Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06698003 · ClinicalTrials.gov registry record · Phase 2
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
A Phase 2 study of Lymphoma and T-cell Leukemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
- 7
- Study locations
NCT06698003 is a Phase 2 study of Lymphoma and T-cell Leukemia that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 134 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (72% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06698003, a Phase 2 study of Lymphoma and T-cell Leukemia, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in some of their immune system cells called T-cells.
Conditions Studied
Interventions
- DRUG Mogamulizumab
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All protocol activities) - Commack
- Memorial Sloan Kettering Westchester (All protocol activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All protocol activities) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge (All protocol activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2024-11-15 |
| Est. Completion | 2029-11-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06698003
The ClinicalTrials.gov registry entry for NCT06698003 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (72% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Mogamulizumab is the first listed.
NCT06698003 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06698003 about?
NCT06698003 is a clinical study titled "A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1". The purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of changes seen in som...
What is the current status of trial NCT06698003?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2024-11-15. Estimated completion is 2029-11-15.
What conditions does trial NCT06698003 study?
This clinical trial studies the following conditions: Lymphoma, T-cell Leukemia, T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma.
What interventions are being tested in trial NCT06698003?
The interventions under investigation include: Mogamulizumab (DRUG).
Who is sponsoring clinical trial NCT06698003?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06698003 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.